These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Chronic intracerebroventricular administration of recombinant CART(42-89) peptide inhibits and causes weight loss in lean and obese Zucker (fa/fa) rats. Larsen PJ; Vrang N; Petersen PC; Kristensen P Obes Res; 2000 Nov; 8(8):590-6. PubMed ID: 11156435 [TBL] [Abstract][Full Text] [Related]
23. Decreased intake of a liquid diet in nonfood-deprived rats following intra-PVN injections of GLP-1 (7-36) amide. McMahon LR; Wellman PJ Pharmacol Biochem Behav; 1997 Nov; 58(3):673-7. PubMed ID: 9329057 [TBL] [Abstract][Full Text] [Related]
24. Solubilization of active GLP-1 (7-36)amide receptors from RINm5F plasma membranes. Göke R; Oltmer B; Sheikh SP; Göke B FEBS Lett; 1992 Apr; 300(3):232-6. PubMed ID: 1313374 [TBL] [Abstract][Full Text] [Related]
25. Internalization of glucagon-like peptide-1(7-36)amide in rat insulinoma cells. Göke R; Richter G; Göke B; Trautmann M; Arnold R Res Exp Med (Berl); 1989; 189(4):257-64. PubMed ID: 2554438 [TBL] [Abstract][Full Text] [Related]
26. A role for glucagon-like peptide-1 in the central regulation of feeding. Turton MD; O'Shea D; Gunn I; Beak SA; Edwards CM; Meeran K; Choi SJ; Taylor GM; Heath MM; Lambert PD; Wilding JP; Smith DM; Ghatei MA; Herbert J; Bloom SR Nature; 1996 Jan; 379(6560):69-72. PubMed ID: 8538742 [TBL] [Abstract][Full Text] [Related]
27. Receptors for glucagon-like peptide-1(7-36) amide on rat insulinoma-derived cells. Göke R; Conlon JM J Endocrinol; 1988 Mar; 116(3):357-62. PubMed ID: 2832504 [TBL] [Abstract][Full Text] [Related]
28. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Larsen PJ; Tang-Christensen M; Jessop DS Endocrinology; 1997 Oct; 138(10):4445-55. PubMed ID: 9322962 [TBL] [Abstract][Full Text] [Related]
29. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP-1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Widmann C; Dolci W; Thorens B Mol Endocrinol; 1996 Jan; 10(1):62-75. PubMed ID: 8838146 [TBL] [Abstract][Full Text] [Related]
30. Intra-islet regulation of hormone secretion by glucagon-like peptide-1-(7--36) amide. Heller RS; Aponte GW Am J Physiol; 1995 Dec; 269(6 Pt 1):G852-60. PubMed ID: 8572216 [TBL] [Abstract][Full Text] [Related]
31. Circulating glucagon-like peptide-1 (GLP-1) inhibits eating in male rats by acting in the hindbrain and without inducing avoidance. Punjabi M; Arnold M; Rüttimann E; Graber M; Geary N; Pacheco-López G; Langhans W Endocrinology; 2014 May; 155(5):1690-9. PubMed ID: 24601880 [TBL] [Abstract][Full Text] [Related]
32. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Al-Barazanji KA; Arch JR; Buckingham RE; Tadayyon M Obes Res; 2000 Jul; 8(4):317-23. PubMed ID: 10933308 [TBL] [Abstract][Full Text] [Related]
33. Effects of intracerebroventricular injection of glucagon like peptide-1 and its related peptides on serotonin metabolism and on levels of amino acids in the rat hypothalamus. Owji AA; Khoshdel Z; Sanea F; Panjehshahin MR; Shojaee Fard M; Smith DM; Coppock HA; Ghatei MA; Bloom SR Brain Res; 2002 Mar; 929(1):70-5. PubMed ID: 11852032 [TBL] [Abstract][Full Text] [Related]
34. Effects of peripheral or central GLP-1 receptor blockade on leptin-induced suppression of appetite. Nowak A; Bojanowska E J Physiol Pharmacol; 2008 Sep; 59(3):501-10. PubMed ID: 18953093 [TBL] [Abstract][Full Text] [Related]
35. Subcutaneous oxyntomodulin analogue administration reduces body weight in lean and obese rodents. Liu YL; Ford HE; Druce MR; Minnion JS; Field BC; Shillito JC; Baxter J; Murphy KG; Ghatei MA; Bloom SR Int J Obes (Lond); 2010 Dec; 34(12):1715-25. PubMed ID: 20531351 [TBL] [Abstract][Full Text] [Related]
36. Effects of substitution of N-terminal amino acid of glucagon-like peptide-1 (7-36) amide on food intake of the neonatal chick. Bungo T; Shimojo M; Masuda Y; Saito N; Sugahara K; Hasegawa S; Furuse M Life Sci; 1999; 65(24):PL295-9. PubMed ID: 10619374 [TBL] [Abstract][Full Text] [Related]
37. Peptide YY3-36 and glucagon-like peptide-17-36 inhibit food intake additively. Neary NM; Small CJ; Druce MR; Park AJ; Ellis SM; Semjonous NM; Dakin CL; Filipsson K; Wang F; Kent AS; Frost GS; Ghatei MA; Bloom SR Endocrinology; 2005 Dec; 146(12):5120-7. PubMed ID: 16150917 [TBL] [Abstract][Full Text] [Related]
38. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells. Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751 [TBL] [Abstract][Full Text] [Related]
39. Central pre-proglucagon derived peptides: opportunities for treatment of obesity. Larsen PJ; Vrang N; Tang-Christensen M Curr Pharm Des; 2003; 9(17):1373-82. PubMed ID: 12769729 [TBL] [Abstract][Full Text] [Related]
40. GLP-1 receptor signaling is not required for reduced body weight after RYGB in rodents. Ye J; Hao Z; Mumphrey MB; Townsend RL; Patterson LM; Stylopoulos N; Münzberg H; Morrison CD; Drucker DJ; Berthoud HR Am J Physiol Regul Integr Comp Physiol; 2014 Mar; 306(5):R352-62. PubMed ID: 24430883 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]